Skip to content
Fall Sale 40% off everything Ends in Offer ends November 30.

Ipamorelin Research Guide: Identity, Literature, Analysis and Documentation

Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.

Ipamorelin is a synthetic pentapeptide with an unusual composition: three of its five residues are not standard amino acids. Aminoisobutyric acid at the N-terminus, D-2-naphthylalanine and D-phenylalanine in the middle, and a C-terminal amide make it resistant to the proteases that clear natural peptides and give it an analytical fingerprint quite unlike a native sequence. This page collects the identity data, the research areas the literature covers, the analytical points those unnatural residues raise, and the report on file for StarBio’s lot.

Identity

Name Ipamorelin (NNC 26-0161)
Type Synthetic pentapeptide, growth hormone secretagogue receptor (GHS-R1a) ligand
CAS number 170851-70-4
Molecular weight 711.85 g/mol
Formula C38H49N9O5
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2
Length 5 residues, C-terminal amide

Origin and history

Ipamorelin was designed at Novo Nordisk in the 1990s as part of a programme of small peptide secretagogues derived from the growth hormone releasing peptides, and was first described in 1998 by Raun and colleagues in the European Journal of Endocrinology [1]. Its development as a medicine did not go beyond clinical trials, and it has no marketing authorisation anywhere; outside the laboratory it is a research chemical. The later literature is mostly receptor pharmacology and rodent or ferret models, with a 2018 paper using ipamorelin-based derivatives as imaging probes.

What the literature covers

The references on file for this compound span several research areas. They are listed here as areas of study, not as results.

  • Original characterisation. The 1998 paper that introduced the molecule [1].
  • Receptor pharmacology. The relationship between growth hormone releasing peptides and ghrelin (2001) [8] and the structural similarity of ghrelin derivatives to peptidyl secretagogues (2001) [10].
  • Rodent models. Glucocorticoid-treated rats: bone formation (2001) [4], nitrogen balance and urea synthesis (2009) [3], and a methylprednisolone study (1999) [7]; somatotroph cultures from young female rats (2002) [5]; a postoperative ileus model (2009) [9].
  • Ferret model. A 2024 Physiology & Behavior study comparing two GHS-R1a agonists in ferrets [2].
  • Imaging chemistry. Peptidomimetic derivatives for positron emission tomography of the ghrelin receptor (2018) [6].

Most primary studies are twenty or more years old and come from the originating company or its collaborators. Read the model before citing.

Analytical notes

Two of the three unnatural residues are D-amino acids, and that has a direct consequence for how a certificate should be read. Standard reverse-phase HPLC separates the molecule from deletion and truncated impurities, and mass spectrometry confirms the mass against C38H49N9O5, but neither method distinguishes a D residue from its L enantiomer; an all-L diastereomer would have the same mass and a nearly identical retention time. Confirming stereochemistry needs a chiral method or a reference standard, which routine certificates do not include, so treat HPLC plus MS as confirming composition and mass rather than full stereochemical identity. The naphthyl group is a strong chromophore, so detection at 220 nm and at 280 nm both work and the two traces should agree. The C-terminal amide is 1 Da lighter than the free acid; a mass spectrum with unit resolution can tell them apart. Aib and the D residues make the molecule unusually stable in solution compared with native peptides, but the lysine salt form still takes up water, so area percent exceeds content by weight (see what 99% purity means).

Storage and stability

  • Lyophilized powder
  • Store at -20 °C
  • Protect from light
  • Avoid repeated freeze-thaw cycles
  • In solution: 2-8 °C, short term

Documentation for StarBio lots

Every StarBio lot is analysed by an independent laboratory. The table lists the report on file for this compound.

Variant Laboratory / report HPLC purity Labelled / measured Tested
Ipamorelin 5 mg Medutest WWB-IP5-5236 99.15% 5 mg Feb 5, 2026 report

Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.

References

  1. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998, PMID 9849822.
  2. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior, 2024, PMID 39043357.
  3. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Hormone & IGF Research, 2009, PMID 19231263.
  4. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 2001, PMID 11735244.
  5. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and Histopathology, 2002, PMID 12168778.
  6. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. European Journal of Medicinal Chemistry, 2018, PMID 30282322.
  7. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Hormone & IGF Research, 1999, PMID 10629165.
  8. Do growth hormone-releasing peptides act as ghrelin secretagogues?. Endocrine, 2001, PMID 11322495.
  9. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 2009, PMID 19289567.
  10. Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues. Biochemical and Biophysical Research Communications, 2001, PMID 11396951.

Product page: Ipamorelin. Related guides: HPLC and mass spectrometry, how to read a certificate, what 99% purity means.

For laboratory research use only. Not for human or veterinary use.

Compared with related compounds: Ipamorelin vs Sermorelin.

Questions about Ipamorelin

What is Ipamorelin?

Ipamorelin is a growth hormone secretagogue (GHS-R1a agonist pentapeptide): 5 residues (pentapeptide), molecular weight 711.85 g/mol, CAS number 170851-70-4. It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.

Is Ipamorelin the same as NNC 26-0161?

Ipamorelin is also listed as NNC 26-0161. On a certificate or vial label, the CAS number (170851-70-4) and the sequence identify the material regardless of which name is used.

What are the CAS number, formula and molecular weight of Ipamorelin?

Ipamorelin has CAS number 170851-70-4, molecular formula C38H49N9O5 and molecular weight 711.85 g/mol. Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Identity of each StarBio batch is confirmed by mass spectrometry on the laboratory report.

Is StarBio's Ipamorelin independently tested?

Yes. The current Ipamorelin batch was tested by Medutest (Medutest report WWB-IP5-5236): 99.15% purity by HPLC, tested Feb 5, 2026. The report is on file in the COA library (report page).

How should Ipamorelin be stored?

Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.

Where can I buy Ipamorelin for laboratory research?

StarBio sells Ipamorelin as 10 mg at $49.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.

New reports and guides, by email

A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.

For laboratory research use only. No dosing or protocol content is ever sent.

StarBio

Researcher verification

StarBio supplies research compounds only to qualified researchers and laboratories, for in vitro laboratory use. Enter your date of birth and confirm your research use to continue.

You must be 21 or older.

By continuing you affirm that the date and statement above are true. Products are supplied for laboratory research only: not for human or veterinary use, not for diagnostic procedures, and not evaluated by the U.S. Food and Drug Administration. Full disclaimer.

Not a researcher? Exit